Limits...
Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands.

Penate Medina O, Haikola M, Tahtinen M, Simpura I, Kaukinen S, Valtanen H, Zhu Y, Kuosmanen S, Cao W, Reunanen J, Nurminen T, Saris PE, Smith-Jones P, Bradbury M, Larson S, Kairemo K - J Drug Deliv (2010)

Bottom Line: Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets.In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle.Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Sloan Kettering Institute for Cancer Research, 1275 York Ave., New York, NY 10065, USA.

ABSTRACT
Nanotechnology offers an alternative to conventional treatment options by enabling different drug delivery and controlled-release delivery strategies. Liposomes being especially biodegradable and in most cases essentially nontoxic offer a versatile platform for several different delivery approaches that can potentially enhance the delivery and targeting of therapies to tumors. Liposomes penetrate tumors spontaneously as a result of fenestrated blood vessels within tumors, leading to known enhanced permeability and subsequent drug retention effects. In addition, liposomes can be used to carry radioactive moieties, such as radiotracers, which can be bound at multiple locations within liposomes, making them attractive carriers for molecular imaging applications. Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets. In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle. Gelatinases as extracellular targets for tumor targeting offer a viable alternative for tumor targeting. Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier plot of the survival of tumor bearing mice.  Mice were treated with doxorubicin (9 mg/kg), administered either as CTT2-SL liposome or Caelyx. Controls were injected with doxorubicin (9 mg/kg) or saline dilution buffer. Injections for each treatment group were made at day 0, day 3 and day 6, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3066593&req=5

fig8: Kaplan-Meier plot of the survival of tumor bearing mice. Mice were treated with doxorubicin (9 mg/kg), administered either as CTT2-SL liposome or Caelyx. Controls were injected with doxorubicin (9 mg/kg) or saline dilution buffer. Injections for each treatment group were made at day 0, day 3 and day 6, respectively.

Mentions: CTT2-SL liposomal antitumor efficacy data following i.v. bolus injections of CTT2-SL liposome, Caelyx, doxorubicin, and buffer in A2780 xenografts is shown in Figure 8. Live mice exhibiting tumor sizes exceeding 1000 mm3 were sacrificed, including those at days 15 and 24 following i.v. administration of buffer or doxorubicin, respectively. Importantly, 80% of mice treated with CTT-SL liposomes and 50% treated with Caelyx were alive at 24 days following initiation of treatment. Treatment with CTT2-SL liposomes was therefore found to increase mean survival times of mice by 38% from 27.9 to 38.6 days.


Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands.

Penate Medina O, Haikola M, Tahtinen M, Simpura I, Kaukinen S, Valtanen H, Zhu Y, Kuosmanen S, Cao W, Reunanen J, Nurminen T, Saris PE, Smith-Jones P, Bradbury M, Larson S, Kairemo K - J Drug Deliv (2010)

Kaplan-Meier plot of the survival of tumor bearing mice.  Mice were treated with doxorubicin (9 mg/kg), administered either as CTT2-SL liposome or Caelyx. Controls were injected with doxorubicin (9 mg/kg) or saline dilution buffer. Injections for each treatment group were made at day 0, day 3 and day 6, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3066593&req=5

fig8: Kaplan-Meier plot of the survival of tumor bearing mice. Mice were treated with doxorubicin (9 mg/kg), administered either as CTT2-SL liposome or Caelyx. Controls were injected with doxorubicin (9 mg/kg) or saline dilution buffer. Injections for each treatment group were made at day 0, day 3 and day 6, respectively.
Mentions: CTT2-SL liposomal antitumor efficacy data following i.v. bolus injections of CTT2-SL liposome, Caelyx, doxorubicin, and buffer in A2780 xenografts is shown in Figure 8. Live mice exhibiting tumor sizes exceeding 1000 mm3 were sacrificed, including those at days 15 and 24 following i.v. administration of buffer or doxorubicin, respectively. Importantly, 80% of mice treated with CTT-SL liposomes and 50% treated with Caelyx were alive at 24 days following initiation of treatment. Treatment with CTT2-SL liposomes was therefore found to increase mean survival times of mice by 38% from 27.9 to 38.6 days.

Bottom Line: Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets.In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle.Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Sloan Kettering Institute for Cancer Research, 1275 York Ave., New York, NY 10065, USA.

ABSTRACT
Nanotechnology offers an alternative to conventional treatment options by enabling different drug delivery and controlled-release delivery strategies. Liposomes being especially biodegradable and in most cases essentially nontoxic offer a versatile platform for several different delivery approaches that can potentially enhance the delivery and targeting of therapies to tumors. Liposomes penetrate tumors spontaneously as a result of fenestrated blood vessels within tumors, leading to known enhanced permeability and subsequent drug retention effects. In addition, liposomes can be used to carry radioactive moieties, such as radiotracers, which can be bound at multiple locations within liposomes, making them attractive carriers for molecular imaging applications. Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets. In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle. Gelatinases as extracellular targets for tumor targeting offer a viable alternative for tumor targeting. Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

No MeSH data available.


Related in: MedlinePlus